Dermatology

In these survey findings, a variety of notable findings regarding perceptions of awareness of CHE as well as views on available drugs are highlighted.

This quiz, the third in a series of 4, tests one's knowledge on prevention and treatment of actinic keratosis based on the 2021 AAD guidelines.

Casale discussed data from the phase 1b/2a BEACON study he presented at the AAAAI/WAO Joint Congress.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

This quiz, the second in a series of 4, tests your knowledge on cryosurgery and PDT recommendations for actinic keratosis based on the 2021 AAD guidelines.

Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.

This Month in Review summary highlights various news highlights featured in February’s dermatology news coverage.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

Castells describes what’s missing from the current treatment landscape and the potential implications of elenestinib for indolent systemic mastocytosis.

John Barbieri, MD, MBA, discusses recent data examining factors associated with formation of benzene in OTC benzoyl peroxide products.

This quiz, the first in a series of 4, tests your knowledge on prevention and treatment of actinic keratosis based on the 2021 AAD guidelines.

Metz shared highlights from 2 presentations he gave on barzolvolimab’s efficacy at the AAAAI/WAO Joint Congress.

Our top 5 headlines include an FDA approval, a pair of submissions, data from AAAAI 2025, and more!

Alexis discussed the latest research in the field and new management strategies for children with atopic dermatitis.

These phase 3 data on delgocitinib cream (Anzupgo) 20 mg/g highlight the drug’s potential for adolescents aged 12 years and older with chronic hand eczema (CHE).

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.

Kernizan discusses winning the 2024 Society for Pediatric Dermatology Medical Student Mentorship Award and getting into pediatric dermatology as a student.

In this analysis, investigators demonstrated that risankizumab led to improvements in palmoplantar pustulosis (PPP) that continued through to Week 68.

These data point to the necessity of quality and usability when using smartphone photographs of skin conditions in emergency departments.

In this interview, Druskovich highlights her experiences being mentored through the Society for Pediatric Dermatology’s Medical Student Mentorship Award.

These data highlight the unique burdens faced by patients with generalized pustular psoriasis (GPP) compared to those of patients with psoriasis vulgaris.

Participants in a phase 3 OLE had a mean monthly attack rate of 0.08.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

On Feb. 26, 2025, Arcutis Biotherapeutics announced the FDA's acceptance of their sNDA for roflumilast cream 0.05% in AD for children aged 2 to 5 years.

Sebetralstat has a PDUFA date of June 12, 2025, for treating HAE in patients 12 years and older.